dalteparin has been researched along with Fetal Growth Retardation in 17 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Fetal Growth Retardation: Failure of a FETUS to attain expected GROWTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 7.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 3.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| "125 women with intrauterine growth restriction were randomized to control group and intervention group (receiving routine high risk pregnancy prenatal care plus daily subcutaneous injection of 40 mg enoxaparin)." | 3.01 | Therapeutic role of enoxaparin in intra-uterine growth restriction: A randomized clinical trial. ( Fathi, M; Golshahi, F; Naeiji, Z; Nazari, F; Sahebdel, B; Sharbaf, FR; Shirazi, M, 2021) |
| "Preeclampsia (PE) and intrauterine growth restriction (IUGR) are major causes of maternal and perinatal morbidity and mortality." | 2.94 | Early Prophylactic Enoxaparin for the Prevention of Preeclampsia and Intrauterine Growth Restriction: A Randomized Trial. ( Alijotas-Reig, J; Bella, M; Burgos, J; Cabero, L; Carreras, E; De Diego, R; Gómez-Roig, MD; Llurba, E; Martínez-Astorquiza, T; Mazarico, E; Sánchez, O; Sánchez-Durán, MÁ, 2020) |
| "The incidence of intrauterine growth restriction (IUGR) is estimated at about 3% of pregnancies, and it is associated with 30% of all perinatal mortality and severe morbidity with adverse neurodevelopmental and cardiovascular health consequences in adult life." | 2.87 | Study protocol for a randomised controlled trial: treatment of early intrauterine growth restriction with low molecular weight heparin (TRACIP). ( Camprubí, M; Figueras, F; Gomez Roig, MD; Ibáñez-Burillo, P; Masoller, N; Mazarico, E; Oros, D; Peguero, A; Rovira, C; Schoorlemmer, J; Tàssies, MD, 2018) |
| "In treated women, the relative risk for preeclampsia was 0." | 2.71 | Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. ( Abbate, R; Fatini, C; Gensini, F; Gensini, GF; Marchionni, M; Mello, G; Parretti, E; Riviello, C; Scarselli, GF, 2005) |
| "The authors report a pregnancy with fetal growth restriction at 36 weeks in a 31-year-old primigravida with symptomatic BD, treated with uninterrupted monthly IFX and daily enoxaparin." | 2.50 | Pregnancy management in Behçet's disease treated with uninterrupted infliximab. Report of a case with fetal growth restriction and mini-review of the literature. ( Correa, R; De Franciscis, P; Della Gala, A; Di Donna, MC; Ercolano, S; Esposito, E; Mainini, G; Stradella, L, 2014) |
| "Women with thrombophilia have an increased risk of pregnancy loss and possibly other serious obstetric complications, although definition of the magnitude of risk will require prospective longitudinal studies." | 2.42 | Thrombophilia and pregnancy complications. ( Kujovich, JL, 2004) |
| "To evaluate the safety of individually dosed low molecular weight heparin (LMWH) for prophylaxis and treatment of thromboembolic complications in pregnancy." | 1.36 | Venous thromboembolism in pregnancy: prophylaxis and treatment with low molecular weight heparin. ( Andersen, AS; Bergholt, T; Berthelsen, JG, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Myasnikova, VV | 1 |
| Galenko-Yaroshevskii, PA | 1 |
| Lysenkov, SP | 1 |
| Gigineishvili, MA | 1 |
| Berberashvili, TM | 1 |
| Mazarico, E | 2 |
| Peguero, A | 1 |
| Camprubí, M | 1 |
| Rovira, C | 1 |
| Gomez Roig, MD | 1 |
| Oros, D | 1 |
| Ibáñez-Burillo, P | 1 |
| Schoorlemmer, J | 1 |
| Masoller, N | 1 |
| Tàssies, MD | 1 |
| Figueras, F | 1 |
| Loussert, L | 1 |
| Mol, BW | 1 |
| Vayssiere, C | 1 |
| Grandone, E | 1 |
| Martinelli, P | 1 |
| Villani, M | 1 |
| Vecchione, G | 1 |
| Fischetti, L | 1 |
| Leccese, A | 1 |
| Santacroce, R | 1 |
| Corso, G | 1 |
| Margaglione, M | 1 |
| Llurba, E | 1 |
| Bella, M | 1 |
| Burgos, J | 1 |
| Gómez-Roig, MD | 1 |
| De Diego, R | 1 |
| Martínez-Astorquiza, T | 1 |
| Alijotas-Reig, J | 1 |
| Sánchez-Durán, MÁ | 1 |
| Sánchez, O | 1 |
| Carreras, E | 1 |
| Cabero, L | 1 |
| Shirazi, M | 1 |
| Naeiji, Z | 1 |
| Sharbaf, FR | 1 |
| Golshahi, F | 1 |
| Fathi, M | 1 |
| Nazari, F | 1 |
| Sahebdel, B | 1 |
| Mainini, G | 1 |
| Di Donna, MC | 1 |
| Esposito, E | 1 |
| Ercolano, S | 1 |
| Correa, R | 1 |
| Stradella, L | 1 |
| Della Gala, A | 1 |
| De Franciscis, P | 1 |
| Mastrolia, SA | 1 |
| Novack, L | 1 |
| Thachil, J | 1 |
| Rabinovich, A | 1 |
| Pikovsky, O | 1 |
| Klaitman, V | 1 |
| Loverro, G | 1 |
| Erez, O | 1 |
| Fernández-Alba, JJ | 1 |
| González-Macías, C | 1 |
| Vilar Sánchez, A | 1 |
| Tajada Cepero, P | 1 |
| Garrido Teruel, R | 1 |
| García-Cabanillas, MJ | 1 |
| Moreno-Corral, LJ | 1 |
| Torrejón Cardoso, R | 1 |
| Bertini, G | 1 |
| Perugi, S | 1 |
| Dani, C | 1 |
| Prisco, D | 1 |
| Fonda, C | 1 |
| Kujovich, JL | 1 |
| Abdulghani, S | 1 |
| Moretti, F | 1 |
| Gruslin, A | 1 |
| Grynspan, D | 1 |
| Andersen, AS | 1 |
| Berthelsen, JG | 1 |
| Bergholt, T | 1 |
| Stone, S | 1 |
| Hunt, BJ | 1 |
| Seed, PT | 1 |
| Parmar, K | 1 |
| Khamashta, MA | 1 |
| Poston, L | 1 |
| Mello, G | 1 |
| Parretti, E | 1 |
| Fatini, C | 1 |
| Riviello, C | 1 |
| Gensini, F | 1 |
| Marchionni, M | 1 |
| Scarselli, GF | 1 |
| Gensini, GF | 1 |
| Abbate, R | 1 |
| Leduc, L | 1 |
| Dubois, E | 1 |
| Takser, L | 1 |
| Rey, E | 1 |
| David, M | 1 |
| Hansen, AT | 1 |
| Sandager, P | 1 |
| Ramsing, M | 1 |
| Petersen, OB | 1 |
| Salvig, JD | 1 |
| Juul, S | 1 |
| Uldbjerg, N | 1 |
| Hvas, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Intrauterine Growth Restriction With Low Molecular Heparin: Randomized Clinical Trial. Tratamiento Del Crecimiento Intrauterino Restringido Precoz Con Heparina de Bajo Peso Molecular: Ensayo clínico Aleatorizado.[NCT03324139] | Phase 3 | 50 participants (Anticipated) | Interventional | 2017-10-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for dalteparin and Fetal Growth Retardation
| Article | Year |
|---|---|
Pregnancy management in Behçet's disease treated with uninterrupted infliximab. Report of a case with fetal growth restriction and mini-review of the literature.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Anticoagulants; Behcet Syndrome; En | 2014 |
LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis.
Topics: Enoxaparin; Female; Fetal Growth Retardation; Heparin, Low-Molecular-Weight; Humans; Pre-Eclampsia; | 2016 |
Thrombophilia and pregnancy complications.
Topics: Abortion, Habitual; Enoxaparin; Factor V; Female; Fetal Growth Retardation; Fibrinolytic Agents; Hum | 2004 |
6 trials available for dalteparin and Fetal Growth Retardation
| Article | Year |
|---|---|
Study protocol for a randomised controlled trial: treatment of early intrauterine growth restriction with low molecular weight heparin (TRACIP).
Topics: Female; Fetal Growth Retardation; Gestational Age; Heparin, Low-Molecular-Weight; Humans; Infant, Ne | 2018 |
Letter to the editor in response to "Therapeutic role of enoxaparin in intra-uterine growth restriction: A randomized clinical trial".
Topics: Anticoagulants; Enoxaparin; Female; Fetal Growth Retardation; Humans | 2022 |
Early Prophylactic Enoxaparin for the Prevention of Preeclampsia and Intrauterine Growth Restriction: A Randomized Trial.
Topics: Enoxaparin; Female; Fetal Growth Retardation; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn | 2020 |
Therapeutic role of enoxaparin in intra-uterine growth restriction: A randomized clinical trial.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Fetal Growth Retardation; Gestational Age; Humans; Pregna | 2021 |
Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women.
Topics: Adult; Anticoagulants; Birth Weight; Circadian Rhythm; Dalteparin; Diastole; Female; Fetal Growth Re | 2005 |
Tinzaparin for the treatment of foetal growth retardation: An open-labelled randomized clinical trial.
Topics: Anticoagulants; Female; Fetal Growth Retardation; Humans; Male; Tinzaparin | 2018 |
8 other studies available for dalteparin and Fetal Growth Retardation
| Article | Year |
|---|---|
Pharmacological correction of hemostasis-regulating function of the lungs in rats with uncomplicated pregnancy and experimental gestosis.
Topics: Animals; Anticoagulants; Birth Weight; Blood Coagulation; Blood Coagulation Disorders; Female; Fetal | 2005 |
Prospective evaluation of pregnancy outcome in an Italian woman with late-onset combined homocystinuria and methylmalonic aciduria.
Topics: Abortion, Spontaneous; Adult; Anticoagulants; Enoxaparin; Female; Fetal Growth Retardation; Homocyst | 2019 |
Birthweight in pregnant women with protein S deficiency treated with low-molecular-weight heparin: a retrospective cohort study.
Topics: Adult; Anticoagulants; Birth Weight; Case-Control Studies; Enoxaparin; Female; Fetal Growth Retardat | 2017 |
Cerebral venous thrombosis treated with enoxaparin in an IUGR neonate with DIC.
Topics: Anticoagulants; Brain; Cerebral Hemorrhage; Cerebral Veins; Cerebrovascular Disorders; Disseminated | 2009 |
Recurrent Massive Perivillous Fibrin Deposition and Chronic Intervillositis Treated With Heparin and Intravenous Immunoglobulin: A Case Report.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Anticoagulants; Aspirin; Chorionic Villi; Daltepar | 2017 |
Venous thromboembolism in pregnancy: prophylaxis and treatment with low molecular weight heparin.
Topics: Adult; Anticoagulants; Cesarean Section; Dalteparin; Female; Fetal Growth Retardation; Fibrinolytic | 2010 |
Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancy.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biomarkers; Dalteparin; Endothelium, Vascular; F | 2003 |
Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia.
Topics: Abruptio Placentae; Adult; Anticoagulants; Aspirin; Dalteparin; Drug Therapy, Combination; Female; F | 2007 |